Back to Journals » OncoTargets and Therapy » Volume 4

Eribulin mesylate as a microtubule inhibitor for treatment of patients with metastatic breast cancer

Authors Muñoz-Couselo E, Pérez-García J, Cortes J

Published 14 November 2011 Volume 2011:4 Pages 185—192

DOI https://doi.org/10.2147/OTT.S16392

Review by Single anonymous peer review

Peer reviewer comments 3



Eva Muñoz-Couselo, José Pérez-García, Javier Cortés
Breast Cancer Unit, Vall d’Hebron Institute of Oncology, Vall d’Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain

Abstract: Metastatic breast cancer (MBC) remains an incurable disease, with the goals of care aimed at maximizing the patient’s duration and quality of life. Treatment options for MBC have become more efficacious and numerous. In addition to endocrine and chemotherapy agents, a number of targeted agents, including trastuzumab and bevacizumab, have further enhanced the landscape of therapeutic options. Eribulin mesylate (E7389) is a nontaxane microtubule dynamics inhibitor, and a structurally simplified synthetic analog of the natural marine product, halichondrin B, with a novel mechanism of action that has shown antitumor activity in pretreated MBC. Eribulin has shown a manageable tolerability profile in Phase I–II clinical trials and an improvement in overall survival compared with treatment of physician’s choice, without relevant toxicities in a recently published Phase III trial. This review will focus on eribulin as a new active agent for MBC and its role in the management of breast disease.

Keywords: metastatic breast cancer, eribulin mesylate, halichondrin B, tubulin-targeted agents

Creative Commons License © 2011 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.